Back to Search
Start Over
Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.
- Source :
-
HIV medicine [HIV Med] 2017 May; Vol. 18 (5), pp. 321-331. Date of Electronic Publication: 2016 Sep 20. - Publication Year :
- 2017
-
Abstract
- Objectives: Human papillomavirus (HPV)-associated cancers disproportionately affect those infected with HIV despite effective combination antiretroviral therapy (cART). The primary aim of this study was to quantify HPV16 and HPV52 E6-specific interferon (IFN)-γ enzyme-linked immunospot (ELISPOT) T-cell responses, a correlate of protective immunity, in the first year following cART initiation and subsequently in those patients with suboptimal (sIR) and optimal (oIR) immune reconstitution.<br />Methods: Ninety-four HIV-infected patients were recruited to the study; a longitudinal cohort of patients recruited just prior to commencing cART and followed up for 48 weeks (n = 27), and a cross-sectional cohort (n = 67) consisting of patients with sIR (CD4 T-cell count < 350 cells/μL) and oIR (CD4 T-cell count > 500 cells/μL) after a minimum of 2 years on cART. Controls (n = 29) consisted of HIV-negative individuals. IFN-γ ELISPOT responses against HPV16 and HPV52 E6 were correlated to clinical characteristics, anal and oral HPV carriage, T-cell maturational subsets, markers of activation, senescence and T-regulatory cells.<br />Results: HPV16 and HPV52 E6-specific T-cell responses were detected in only one of 27 patients (3.7%) during the initial phase of immune recovery. After at least 2 years of cART, those who achieved oIR had significantly higher E6-specific responses (9 of 34; 26.5%) compared with those with sIR (2 of 32; 6.3%) (P = 0.029). Apart from higher CD4 T-cell counts and lower CD4 T-cell activation, no other immunological correlates were associated with the detection of HPV16 and HPV52 E6-specific responses.<br />Conclusions: HPV16 and HPV52 E6-specific IFN-γ T-cell responses, a correlate of protective immunity, were detected more frequently among HIV-infected patients who achieved optimal immune recovery on cART (26.5%) compared with those with suboptimal recovery (6.3%).<br /> (© 2016 British HIV Association.)
- Subjects :
- Adult
Cross-Sectional Studies
Enzyme-Linked Immunospot Assay
Female
Genotype
Humans
Interferon-gamma metabolism
Leukocytes, Mononuclear immunology
Longitudinal Studies
Male
Middle Aged
Anti-Retroviral Agents therapeutic use
Antiretroviral Therapy, Highly Active
HIV Infections complications
HIV Infections drug therapy
Oncogene Proteins, Viral immunology
Papillomaviridae immunology
Papillomavirus Infections immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1468-1293
- Volume :
- 18
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- HIV medicine
- Publication Type :
- Academic Journal
- Accession number :
- 27649852
- Full Text :
- https://doi.org/10.1111/hiv.12432